Identification of high-penetrance breast cancer genes such as Brca1 has been accomplished by analysing familial cases. However, these genes occur at low frequency and do not account for the majority of genetic risk. Identification of low-penetrance alleles that occur commonly in populations may benefit from unbiased genome-wide screening. One such approach uses linkage studies in rodent models to identify homologous human candidates. The Wistar Kyoto (WKy) rat is resistant to mammary carcinomas induced with 7,12-dimethybenz[a]anthracene (DMBA), whereas the Wistar Furth (WF) strain is susceptible. Previous genome-wide linkage studies in crosses of these strains identified three WKy resistance quantitative trait loci, Mcs5, Mcs6 and Mcs8, and one predicted to increase susceptibility, Mcs7. The Mcs7 region on rat chromosome 10 (RNO10) is orthologous to human 17q, a common site of genetic aberrations in breast cancer. Here, we establish the independent phenotype conferred by Mcs7 using congenic rats carrying the WKy Mcs7 locus on a WF background. Tumor multiplicity was significantly higher (B50%) in DMBA-treated congenics homozygous and heterozygous for the WKy allele at the Mcs7 locus, compared to controls. We also investigated allelic imbalance (AI) in mammary carcinomas from (WKy Â WF)F1 rats and Mcs7 heterozygous congenics. Of the four known WKy Mcs loci tested, only Mcs7 displayed AI. The pattern of AI in carcinomas from both F1 and Mcs7 congenic rats was similar, suggesting a WF allelic loss. Together, these data suggest that one or more breast cancer-related genes are located within the dominantly acting WKy allele at the Mcs7 locus.
Introduction
Breast cancer risk is a complex trait controlled by the interaction between environmental and hereditary factors. Analysis of cancer concordance in twins has shown that the contribution of genetic factors to breast cancer risk is estimated to be at least 30% (Lichtenstein et al., 2000; Peto, 2000) . The known breast cancer susceptibility genes including BRCA1, BRCA2, TP53 and PTEN have relatively high penetrance, but occur at low frequency in the population (reviewed by Thompson and Easton, 2004) . Collectively, known breast cancer risk alleles account for approximately 20% of increased risk in hereditary cases (Easton, 1999) . Therefore, variation in multiple genes that have lower penetrance but which occur more frequently in the population, combined with environmental and lifestyle factors, contributes significantly to sporadic breast cancer risk.
Strategies to identify lower-penetrance disease-associated variants have resulted from biased candidate gene selection, involving testing of genes most likely to be functionally related to breast carcinogenesis, such as those that function in DNA repair or hormone metabolism (Dumitrescu and Cotarla, 2005 ). However, when tested in large case-control studies, the great majority of these genes have not shown a significant association with breast cancer risk (Thompson and Easton, 2004 ). An analysis of 400 common single nucleotide polymorphisms in approximately 2300 breast cancer cases and 2300 controls did not identify statistically significant associations with the disease (Ponder et al., 2005) . Although the bias of this approach to pick candidates will be removed in the future by genome-wide scanning for allele variants and testing for association in large case-control studies, this strategy is not feasible using current technology. Alternatively, whole-genome linkage studies using animal models for cancer provide an unbiased approach for candidate gene-locus identification. Recently, this approach was used to identify and associate Ptprj, a mouse-defined modifier, with breast cancer risk .
Our laboratory has used linkage analyses of backcross data from inbred rat strains to identify modifiers of susceptibility to mammary cancer. These studies have resulted in the identification of eight significant quantitative trait loci (QTL) in two strains that are resistant to 7,12-dimethybenz [a] anthracene (DMBA)-induced mammary carcinogenesis, Mcs1-4 in the Cop strain (Shepel et al., 1998) and Mcs5-8 in the Wistar Kyoto (WKy) strain (Lan et al., 2001) . Each strain has three resistance loci and one susceptibility locus. The current study focuses on the WKy susceptibility locus, Mcs7. Previous linkage analyses of (WKy Â WF)F1 Â WF and WF Â (WKy Â WF)F1 backcross rat data defined the Mcs7 QTL on rat chromosome 10 (RNO10) (B45 cM). The significant logarithm of odds (LOD) interval was located in the distal region. In the current study, we report increased susceptibility to mammary cancer in DMBA-treated congenic rats in which the WKy allele of the Mcs7 QTL was placed on a Wistar Furth (WF) genetic background.
It is possible that the Mcs7 susceptibility locus may contain a gene that fits the tumor suppressor paradigm, where inheritance of an allele predisposing for cancer is accompanied by somatic inactivation of the normal allele by mutation or loss of heterozygosity (LOH) during carcinogenesis (Knudson, 1971) . Screening for allelic imbalance (AI) in the DNA from solid tumors is commonly used to look for indications of potential tumor suppressor genes. Using this strategy, previous studies estimating the allelic ratio in (WF Â Cop)F1 heterozygous mammary carcinoma DNA relative to that of control DNA in the Cop Mcs1-4 resistance and susceptibility loci showed no AI Shepel et al., 1998) . Here, we looked for evidence of somatic AI in four WKy Mcs loci, and found an allelespecific imbalance only within the Mcs7 QTL.
Results

Phenotypic analysis of congenics
Congenic line D was generated for phenotypic assessment with DMBA. This line contains the significant LOD region of the Mcs7 QTL (Figure 1) , and spans the region between markers D10Got124 and D10Mgh1. Line D was originally shown to contain a region spanning B21 cM (between markers Brca1 and D10Mgh1), but was later determined to extend distally to D10Rat187, and proximally to D10Got124, when additional markers became available for testing. The size of the Mcs7 interval contained by congenic line D is B24.7 Mb (estimated B25 cM). All markers used in genotyping of Mcs7 carriers are shown in Table 1 . Genotyping was carried out to select Mcs7 carriers that lacked the previously predicted WKy resistance and modifier loci, Mcs5, Mcs6, Mcs8 and mMcs1, located on RNO5, RNO7, RNO14 and RNO6, respectively (Lan et al., 2001) . Additional screening for markers on all other rat chromosomes was carried out to select carriers that had lost the WKy allele. The density of these markers was approximately 3-15 cM. Tumor multiplicity (Figure 2 ) in WKy/WF-heterozygous (n ¼ 62) and WKy-homozygous (n ¼ 46) congenic rats was 9.9 and 10.6 tumors/rat, respectively, significantly higher (Po0.01) than that of littermates derived from this line having the WF genotype (n ¼ 43) and rats from the parental WF strain (n ¼ 29) (6.9 tumors/rat for both groups). Thus, the WKy allele at the Mcs7 locus acts in a dominant manner.
Allelic imbalance analysis of (WKy Â WF)F1 carcinoma epithelium Allelic imbalance determination was carried out using acrylamide gel electrophoresis. Although this technique is semiquantitative, our analysis suggests that the AI at the Mcs7 locus is owing to the LOH. Using 11 epithelial preparations obtained from F1 carcinomas (Set 1), preliminary screening of WKy Mcs loci showed no AI in Mcs5, Mcs6 and Mcs8, except for one marker on RNO5, for which one epithelial preparation showed AI (Table 2) . No AI was detected using markers from RNO12 and RNO15, which did not contain significant WKy QTL (Lan et al., 2001) . Using these 11 carcinomas (Set 1) and an additional set of seven (Set 2), AI was observed in 10/18 carcinomas in the Mcs7 region (Table 3 and Figure 3a ). When data for both sets of carcinomas were combined, the frequency of Mcs7 AI in individual markers ranged from 16.7 to 38.9%, with the highest incidence at D10Rat15. Figure 3a approximate genome position of each marker based on the sequencing of the genome of the Brown Norway rat (http://genome.ucsc.edu/). All cases of AI appeared to have reduced PCR product for the WF allele.
Allelic imbalance analysis of WF.WKy-Mcs7 congenics
The panel of RNO10 markers used in AI screening of F1 carcinomas was also used in AI analysis of Mcs7 congenic carcinomas (Figure 3b ), except that D10Got151 was substituted for gUwm59-35. Allelic imbalance in the Mcs7 region occurred in 11/20 carcinoma epithelial preparations from WF.WKy-Mcs7 heterozygous congenics. In all but one case, the WF allele PCR product appeared to be reduced. The incidence of WF AI at each marker ranged from 10.0 to 30.0%.
Discussion
The WKy rat, which is resistant to induced mammary cancer, has QTL that contribute to both resistance and 
Markers
RNO1
D1Rat2, D1Mgh2, D1Rat14, D1Mit9, D1Mgh5, D1Rat39, D1Mgh11, D1Wox25, D1Mgh15
D5Wox8, D5Uwm8, D5Wox7, D5Uwm13, D5Rat82, D5Mgh26, D5Rat68, D5Uwm1, D5Rat64, D5Rat53, D5Rat23, D5Uwm28, D5Mgh23, D5Mgh23, D5Rat26, D5Uwm30, D5Rat28, D5Uwm37, D5Rat33, D5Mgh8, D5Rat39, D5Uwm43, D5Uwm44, D5Uwm46, D5Rat47, D5Uwm50, D5Wox10
Abbreviations: QTL, quantitative trait locus; WKy, Wistar Kyoto. The average number of carcinomas/rat for each genotype was determined 15 weeks following induction with 65 mg/kg body weight DMBA. The tumor multiplicities for WKy/WF-heterozygous (n ¼ 62) and WKy-homozygous (n ¼ 46) congenics were each significantly higher than that for WF controls (n ¼ 29) and WF-homozygous littermates (n ¼ 43) (*Po0.01, Scheffe's test), but did not differ from each other. 
Abbreviations: AI, allelic imbalance; WF, Wistar Furth; WKy, Wistar Kyoto.
Mcs7 allelic imbalance and mammary cancer susceptibility MS Cotroneo et al susceptibility to mammary cancer (Lan et al., 2001 ). This provides an excellent model for the polygenic etiology of breast cancer, in which inherited risk is controlled by the additive and interactive effects of multiple risk loci, each contributing to either increased or decreased susceptibility. Previously, the only WKy QTL that has been phenotyped in congenics is the Mcs5 resistance locus (Samuelson et al., 2003) . Here, we assessed the independent effect of the WKy Mcs7 locus (in the absence of resistance loci Mcs5, Mcs6 and Mcs8) and established the predicted phenotype of increased susceptibility to DMBA-induced mammary carcinogenesis. Two copies of the WKy allele at the Mcs7 locus resulted in a 53% increase in susceptibility over that of the WF. Similarly, one copy increased tumor multiplicity by 43%, suggesting that a dominantly inherited genetic element(s) in this region controls this trait. However, the Mcs7 congenic interval tested is large (B25 cM or B24.7 Mb) and may contain multiple independent loci that individually contribute to risk. This was the case for the Cop Mcs1 resistance QTL, which contained at least three loci (Mcs1a-c), all independently conferring the resistant phenotype . Additionally, the WKy Mcs5 resistance QTL was recently found to contain two independent resistance loci and a locus conferring increased susceptibility, with an epistatic interaction occurring between two of these sub-loci (Samuelson et al., 2005) . Therefore, ongoing testing of additional recombinant congenic lines for Mcs7 has the potential to document a more complex genetic structure. 
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Given the large size of this susceptibility locus, additional fine-mapping studies are needed to narrow the interval(s) associated with the trait so that potential candidate genes can be selected for testing. However, some genes related to breast cancer can be ruled out. Rat chromosome 10 harbors the breast cancer susceptibility gene p53, as well as the neu gene, which is frequently amplified in breast cancer cases. These genes are excluded as candidates because their location is proximal to the Mcs7 congenic interval. However, we cannot exclude Brca1 as a potential candidate at this time.
The carcinogenic process occurs in multiple stages. Although an inherited modifier allele may predispose for cancer development, somatic aberrations such as LOH that occur during progression also play a role in carcinoma development. The identification of loci containing frequent LOH in solid tumors indicates the presence of genes with tumor suppressor function or others involved in carcinoma development (Lasko et al., 1991; Newton and Lee, 2000) , and LOH is the most commonly occurring somatic aberration in human breast cancer (Callahan et al, 1993) . The Mcs7 locus is homologous to mouse chromosome 11 (MMU11) and shares homology with human chromosome 17q. Allelic imbalance in these regions is common to cancer in all three species. Distal 10q in the rat was found to contain regions of AI in cancer models using other strains and carcinogens. A high incidence of AI was identified in this region in mammary carcinomas from (Sprague-Dawley Â F344)F1 rats given 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) or DMBA (Toyota et al., 1996) and in PhIP-treated Sprague-Dawley rats (Yu et al., 2000) . In rat endometrial adenocarcinoma, several regions of AI were identified (Norlander et al., 2005) , including one overlapping Mcs7. Chromosomal gains have also been shown to occur frequently in this region. An area of common gain that overlaps our region of AI was identified in rat and mouse neuroblastoma cell lines (Lastowska et al., 2004) and human neuroblastoma (Lastowska et al., 2002) . Most importantly, large-scale LOH analyses of chromosome 17 in sporadic human breast carcinomas identified several regions of interstitial and terminal deletions in 17q, including loci associated with negative estrogen receptor status and poor prognosis (Phelan et al., 1998) .
Our characterization identified AI that was unique to Mcs7 in (WKy Â WF)F1 mammary carcinomas and was not found in the other WKy loci, Mcs5, Mcs6 and Mcs8. These F1 analyses allowed us to assess WKy genes both inside and outside of the Mcs7 interval that may select for AI in Mcs7 genes. If this was the case, we would expect AI incidence to be higher in carcinomas from F1 rats, compared to those from congenic animals, where the only remaining WKy alleles are located in the Mcs7 region. However, when compared, the pattern and incidence of Mcs7 AI in carcinomas from F1 and congenic rats was similar. We observed AI in one or more Mcs7 markers in B55% of carcinomas from either group. For both groups, B1/3 of AI cases showed a large region of imbalance, whereas the majority showed smaller areas, which were often interspersed between regions where a normal allelic ratio was retained. Of these carcinomas with smaller regions of apparent loss, most F1 carcinomas showed AI near D10Rat15. Carcinomas from congenic rats showing smaller regions of loss had a high frequency of AI at this marker. Interestingly, the gene for growth hormone, important in mammary gland development, is located near D10Rat15.
Another important characteristic of Mcs7 AI is allele specificity. In all but one case, the PCR product for the WF allele was reduced in carcinomas from F1 and congenic rats, suggesting allelic loss. This observation, when considered alone, is consistent with the two-hit hypothesis, where a mutant WKy Mcs7 allele is inherited and the remaining WF copy undergoes somatic LOH during tumor progression, resulting in inactivation. In contrast, our phenotyping results for carcinoma frequency suggest a dominant inheritance of the phenotype of increased susceptibility. This suggests that one copy of the WKy susceptibility allele alone is sufficient to cause this phenotype, and that the second 'hit' (WF LOH) is unlikely to be required. However, the interpretation of the finding of dominance of the WKy allele at the Mcs7 locus may be an oversimplification, in that the rat Mcs7 QTL may be a composite of several interacting loci. Therefore, some dominantly acting inherited WKy susceptibility gene(s) may be distinct from the loci with WF allelic loss. Alternatively, these two events could occur in the same gene but during different stages of carcinogenesis, following the two-hit paradigm. Several rat cancer models fit the two-hit hypothesis and demonstrate the complexity of the underlying genetics. The Eker and Nihon rats, models for hereditary renal cancer, carry mutations in the Tsc2 (Hino et al., 2001) and Bhd (Okimoto et al., 2004 ) genes, respectively. These genes are located on RNO10, proximal to the region of Mcs7 described here, but are contained within the full congenic interval defined from previous linkage analysis (Lan et al., 2001) . A model for chemically induced schwannoma provides an example of polygenic, multistage carcinogenesis involving RNO10. A mutation in the Erbb-2/neu gene was found to occur at an early stage of carcinogenesis (Bargmann et al., 1986) , followed by loss of the remaining copy of this gene later (Nikitin et al., 1991) . Frequent AI occurring after this initiating event was found in schwannomas on RNO5 and RNO10 (Koelsch et al., 2002) . Two regions of loss were identified on RNO10, with one showing allele specificity, the Dis1 locus (Kindler-Ro¨hrborn et al., 1999) . Interestingly, this locus is contained in the Mcs7 region, although distal to the area of maximal linkage.
The WKy rat provides a model for human breast cancer in that it contains several loci that individually confer resistance or susceptibility, with a net effect of resistance. Here, we established the trait of increased susceptibility to mammary cancer conferred independently by Mcs7, and reported the finding of allele-specific genomic imbalance in carcinomas, a characteristic not found in other Mcs loci. The observation of AI in a susceptibility locus allows us to hypothesize that this region contains a gene with tumor suppressor function. However, the apparent dominant inheritance of the trait of increased susceptibility suggests that multiple genes may underlie these two observations. Ongoing studies will aid in fine-mapping the traits of susceptibility and AI and in finding candidate genes at the WKy Mcs7 QTL. Future studies may reveal multiple loci in the Mcs7 QTL that could participate at different or multiple times during the initiation, promotion and progression stages of breast cancer.
Materials and methods
Animal breeding to obtain (WKy Â WF)F1 and WF.WKy-Mcs7 congenic rats All animal studies were carried out in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC). Rats from the WF and WKy parental strains were obtained from Harlan Sprague-Dawley (Indianapolis, IN, USA), and housed in our facility under a 12 h light/dark cycle. Animals were fed Teklad chow and given acidified tap water, ad libitum. Wistar Kyoto female rats were bred with WF males to generate (WKy Â WF)F1 female offspring. Female F1 rats were used for AI determination in DMBA-induced mammary carcinomas, whereas the male F1 rats were used for the initiation of Mcs7 congenic lines by backcrossing them to WF female rats. With each subsequent generation, heterozygous male rats carrying the WKy Mcs7 locus were identified by genotyping of polymorphic microsatellite markers and bred to WF females, as described below. Multiple independent rat lines were generated to allow the region to be divided into smaller segments as a result of recombination events. In the N7 generation, a recombinant line (D) was derived from one of these lines. Congenic line D was used for AI studies and for phenotypic assessment. For determination of AI in mammary carcinomas, N8 generation female heterozygous carriers were obtained. For phenotyping, animals from the N9F2, N10 and N11 generations were used. Heterozygous N9 generation male and female carriers were intercrossed to provide WKy-homozygous and WKy/WFheterozygous N9F1 offspring, which were then crossed to obtain N9F2 WKy-homozygous and WKy/WF-heterozygous female rats for phenotyping. Additional N10 generation WKy/ WF-heterozygous females were generated by the backcross of N9F2 WKy-homozygous males to WF females. To obtain N10 and N11 WF-homozygous control animals, N9 and N10 heterozygous male carriers were backcrossed to female WF rats. Female WF control rats were purchased from the vendor.
DNA isolation and genotyping of congenic rats
To obtain DNA for genotyping, a small piece of tail tissue was removed from each rat. Isolation of DNA was carried out by overnight digestion at 551C using proteinase K, as described previously (Samuelson et al., 2003) . PCR amplification of microsatellite markers was carried out and the products resolved on agarose gels using protocols detailed elsewhere (Samuelson et al., 2003) . Primer sets for all markers were purchased from Research Genetics/Invitrogen (Carlsbad, CA, USA), except for Brca1 primers, which were designed in our laboratory (Chen et al., 1996) and synthesized by the University of Wisconsin Biotechnology Center. Sequences for forward and reverse primers for Rat-, Mit-, AU-, Mgh-and gene markers are available on the UCSC Genome Browser (http://genome.ucsc.edu/), version 3.1. Primer sequences for Uwm markers on RNO5 are published (Lan et al., 1999) . The sequences for the remaining forward and reverse primers for UW-, Uwm-and gUwm-markers, designed in our laboratory, are as follows: UW121: Carcinoma induction for allelic imbalance analysis and phenotyping At 50-55 days of age, rats were given 65 mg DMBA/kg body weight (ACROS Organics, Fisher Scientific, Pittsburgh, PA, USA), dissolved in sesame oil, by gastric lavage. Congenic animals for phenotypic assessment were killed 15 weeks after DMBA administration. All tumors larger than 3 mm in diameter were counted. Tumor histology was evaluated by light microscopic analysis of paraffin sections stained with hematoxylin and eosin to confirm the presence of carcinomas. The average number of carcinomas per rat was determined for each group and compared statistically using one-way ANOVA with multiple comparisons by Sheffe's test (StatView, SAS, Cary, NC, USA). For AI assessment in N8 heterozygous congenics, necropsy was conducted 15 weeks after DMBA administration, whereas in F1 rats, a longer time period (20 weeks) was allowed for carcinoma development owing to low tumor multiplicity (o1 carcinoma/rat). At necropsy, mammary carcinomas and spleens (serving as a normal control) for AI studies were collected from each tumor-bearing rat. For congenic rats, which had multiple tumors (average B11/rat), one carcinoma per rat was randomly selected.
Preparation of epithelial carcinoma cells for allelic imbalance analysis A portion of each carcinoma (>5 mm 2 ) was digested with collagenase at 371C for 16-18 h, digested with DNAse and passed through a 53-mm filter to obtain epithelial-enriched preparations, as described previously . The resulting preparations were frozen in liquid nitrogen and stored at À801C until analysis.
Allelic imbalance determination
To obtain genomic DNA for AI analysis, epithelial-enriched preparations and spleens were digested overnight at 551C in buffer containing proteinase K as described previously (Samuelson et al., 2003) . Initial screening for AI in a subset (Set 1) of (WKy Â WF)F1 epithelial preparations (n ¼ 11) was carried out on regions of all WKy chromosomes containing significant QTL, that is, chromosomes 5, 7, 10 and 14, and on regions of chromosomes 12 and 15 that do not contain significant QTL. Primers for all chromosome 10 markers (excluding Brca1) were obtained from Research Genetics/ Invitrogen and their sequences are available from the UCSC genome browser (http://genome.ucsc.edu/). The primer sequences for gUwm59-30 and gUwm59-35, designed in our laboratory, are 5 0 -CAC CTC ATC CTC GTC CTT TT-3 0 and 5 0 -GGC TGT GAG AGC TTA TGT TGG-3 0 ; and 5 0 -TCA GTC CCA CAA GTT CAA TGA T-3 0 and 5 0 -TGT CAA CTG CAA CTC TCT GTG TT-3 0 , respectively. For each carcinoma DNA sample and corresponding spleen DNA sample, PCR was conducted using 32 P-labelled dATP as described previously . The samples were resolved on 5% acrylamide sequencing gels after being denatured at 941C for 2 min. The gels were then exposed to a phosphor screen, scanned using a Storm Imaging System (GE Healthcare, Piscataway, NJ, USA) and quantitatively analysed with ImageQuant software (GE Healthcare, Piscataway, NJ, USA). Allelic imbalance was defined as a 25% or greater difference in the ratio of radionuclide incorporation into the PCR products of the individual alleles of the carcinoma DNA sample relative to the amount of radionuclide incorporation into the individual alleles of the control spleen DNA sample. This analysis does not distinguish between loss and gain of chromosomal material in the carcinoma. Criteria for AI were (1) at least half of the quantitative analyses for each carcinoma at a specific marker was at or above the AI threshold of a 25% difference, with a minimum of three independent reactions showing AI, and (2) the average percentage difference of all the quantitative analyses for each carcinoma at a marker was at or above a 25% difference. Similar criteria have been used previously .
